BamSEC and AlphaSense Join Forces
Learn More

Roivant Sciences Ltd. – Material Contracts

NASDAQ: ROIV    
Share price (5/26/26): $29.66    
Market cap (5/26/26): $21.3 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K/A 31 pages Settlement Agreement
12/34/56
EX-10.7
from 10-Q 2 pages Special Equity Award Opportunity Letter Eric Venker President and Chief Operating Officer July 26, 2024
12/34/56
EX-10.4
from 10-Q 7 pages Immunovant, Inc. 2019 Equity Incentive Plan Capped Value Appreciation Right Award Grant Notice
12/34/56
EX-10.3
from 10-Q 16 pages Employment Agreement
12/34/56
EX-10.2
from 10-Q 15 pages Amended and Restated Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Dear Jenni,
12/34/56
EX-10.38
from 10-K 9 pages Consulting Agreement
12/34/56
EX-10.37
from 10-K 14 pages Rakhi Kumar [...] Re: Separation Agreement and General Release Dear Rakhi,
12/34/56
EX-10.36
from 10-K 11 pages Roivant Sciences Ltd. Performance Restricted Stock Unit Award Grant Notice
12/34/56
EX-10.35
from 10-K 1 page One-Time Retentive Cash Award Statement [Name] [Title] Dear [Name], in Recognition of Your Hard Work and Dedication and in Anticipation of Your Future Contributions to Roivant and the Vants, We Are Pleased to Provide You With the Following Long-Term Cash Incentive Award (“Cash Award”). Total Award: $[X] Cash Award Payment Dates1 2 to Be Paid Prior to [Date] $ [50%] to Be Paid on September 20, 2024 $ [25%] to Be Paid on September 19, 2025 $ [25%] I Would Like to Take This Opportunity to Thank You for Your Valuable Contributions and Sheer Force of Will. Your Efforts Truly Made This a Remarkable Year at Roivant. Best Regards,
12/34/56
EX-10.34
from 10-K 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Roivant Sciences Ltd. (The “Company”) Has Determined That the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to the Company if Publicly Disclosed
12/34/56
EX-10.46
from 10-Q 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Roivant Sciences Ltd. (The “Company”) Has Determined That the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. Amendment to the License Agreement Dated July 27, 2023
12/34/56
EX-10.45
from 10-Q 54 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Roivant Sciences Ltd. (The “Company”) Has Determined That the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. License Agreement
12/34/56
EX-10.44
from 10-Q 12 pages Executive Employment Agreement
12/34/56
EX-10.43
from 10-Q 13 pages Executive Employment Agreement
12/34/56
EX-10.42
from 10-Q 87 pages First Amendment to Revenue Interest Purchase and Sale Agreement
12/34/56
EX-10.41
from 10-Q 72 pages Second Amendment to Funding Agreement
12/34/56
EX-10.45
from 10-K 12 pages Separation and Mutual Release Agreement
12/34/56
EX-10.44
from 10-K 8 pages Roivant Sciences Ltd. Restricted Stock Unit Award Grant Notice
12/34/56
EX-10.43
from 10-K 10 pages Roivant Sciences Ltd. Stock Option Grant Notice
12/34/56